• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Intarcia Says Phase 3 Results Show Better Control Than Januvia for Type 2 Diabetes Mellitus

Evidence-Based Diabetes ManagementSeptember 2015
Volume 21
Issue SP13

The matchstick-like delivery system has been seen as game-changer in overcoming poor adherence. Filing for FDA approval is anticipated in early 2016.

Intarcia Therapeutics Inc has released topline results for ITCA 650, the implantable device that can deliver up to a year’s worth of exenatide, and said patients with type 2 diabetes mellitus (T2DM) in a phase 3 clinical trial experienced results superior to those of patients treated with sitagliptin, marketed as Januvia.

In results released August 18, 2015,1 the company said patients treated with 60 mcg/d of exenatide saw an average reduction in glycated hemoglobin (A1C) of 1.5%, compared with the average reduction of 0.8 % ( P <.001) for patients taking 100 mg/d of sitagliptin. The patients who were delivered exenatide, a widely used GLP-1 receptor agonist, also experienced greater weight loss, an average of 4 kg, compared with an average loss of 1.3 kg for the sitagliptin group.

The company also reported that more patients in the ITCA 650 group achieved the American Diabetes Association (ADA)-recommended target of <7% A1C. The phase 3 FREEDOM-2 trial involved 535 adult patients with T2DM who were treated for 52 weeks, with a 4-week post treatment follow-up period. All had an A1C of at least 7.5% but not greater than 10.5%. All patients were treated with background metformin and were randomized 1:1 for treatment with either sitagliptin or with exenatide through the unique delivery system, in which a matchstick-like device is placed under the skin to continuously administer tiny doses of the drug, ensuring perfect adherence.

Intarcia is expected to file for a regulatory approval in the first half of 2016, according to the statement from the company. “If approved, ITCA 650 would be the first and only GLP-1 receptor agonist to offer a viable alternative to regular, lifelong injections, and with once or twice yearly dosing it has the potential to enhance patient compliance, which has been a long-standing, unresolved problem and a major contributing cause of poor glycemic control over time,” said Robert R. Henry, MD, chief of the VA Endocrinology and Metabolism Section and professor of medicine in residence at the University of California San Diego, and an investigator in the phase 3 trial.

The data, he said, leave little doubt about the value of the delivery system in tackling the vexing problem of medication adherence, which has been a huge obstacle to achieving glycemic control in certain patient populations. ITCA 650’s performance head-to-head against sitagliptin is compelling in light of sitagliptin’s worldwide sales of $6 billion, said Intarcia president and CEO Kurt Graves.

Sitagliptin, a DPP-4 inhibitor, scored a major victory earlier this year when it demonstrated no cardiovascular effects in the TECOS trial, especially relative to its closest competitor; topline results were released in late April and the full study was presented in June at the Scientific Sessions of the American Diabetes Association.2 But ITCA 650 was a star at the ADA sessions in its own right, with scores of visitors crowding the booth to watch demonstrations of how the tiny drug-fueled piston was inserted under the skin. A large crowd packed a conference session to hear promising results.3

While the company reported the weight loss results, it noted in its statement that ITCA 650 is not yet being investigated for management of obesity. Full data will be reported at an upcoming major medical meeting.1References

1. Intarcia announces new top-line phase 3 results for investigational therapy ITCA 650 in type 2 diabetes [press release]. Boston, MA: PRNewswire; August 18, 2015. http://www.prnewswire.com/news-releases/intarciaannounces-new-top-line-phase-3-results-for-investigationaltherapy-itca-650-in-type-2-diabetes-300130400.html.

2. Caffrey MK. Sitagliptin does not cause adverse cardiovascular effects, TECOS trial finds. Conference Coverage, 75th Scientific Sessions of American Diabetes Association. American Journal of Managed Care website. http://www.ajmc.com/conferences/ADA2015/Sitagliptin-Does-Not-Cause-Adverse-Cardiovascular-Effects-TECOS-Trial-Finds. Published June 9, 2015. Accessed August 21, 2015.

3. Caffrey MK. ITCA 650 results point to “transformational” method to deal with poor adherence in T2DM. American Jounral of Managed Care website. http://www.ajmc.com/conferences/ADA2015/ITCA-650-Results-Point-to-Transformational-Method-to-Deal-with-Poor-Adherence-in-T2DM. Published June 9, 2015. Accessed August 21, 2015.

Related Videos
Chase D. Hendrickson, MD, MPH
Steven Coca, MD, MS, Icahn School of Medicine, Mount Sinai
Matthew Crowley, MD, MHS, associate professor of medicine, Duke University School of Medicine.
Susan Spratt, MD, senior medical director, Duke Population Health Management Office, associate professor of medicine, division of Endocrinology, Metabolism, and Nutrition,
Stephen Nicholls, MD, Monash University and Victorian Heart Hospital
Amal Agarwal, DO, MBA
Dr Robert Groves
Dr Robert Groves
Jeremy Wigginton, MD
Related Content
© 2023 MJH Life Sciences
All rights reserved.